UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE13a-16 OR15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of June 2018
Commission File Number:001-32001
Aptose Biosciences Inc.
(Translation of registrant’s name into English)
251 Consumers Road, Suite 1105
Toronto, Ontario M2J 4R3
Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form20-F ☐ Form40-F ☑
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1) ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7) ☐
INCORPORATION BY REFERENCE
This Report on Form6-K is hereby incorporated by reference (i) as an Exhibit to the Registration Statement on FormF-10 of Aptose Biosciences Inc. (FileNo. 333-222909) and (ii) into the registration statement on FormF-3 of Aptose Biosciences Inc.(File No. 333-221783) and the prospectus included therein.
DOCUMENTS FILED AS PART OF THIS FORM6-K
Exhibit | Description | |
| 99.1 | Material Change Report, dated June 29, 2018 | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Aptose Biosciences Inc. | ||||||
| Date: June 29, 2018 | By: | /s/ Gregory Chow | ||||
| Name: Gregory Chow | ||||||
Title: Senior Vice President and Chief Financial Officer | ||||||
3